Sosei Co., Ltd
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Sosei Co., Ltd
The merger closed in May, so the second quarter earnings report will be the first presentation of the combined company’s performance and outlook.
New York biotech is partnering with researchers at Columbia, Kansas State and Southern Research to address the pandemic.
Japan’s regulators have approved a large batch of new products, including a novel antibody from Chugai, two world-first nods for the country’s second HIF-PH inhibitors and an asthma therapy, and the first Humira biosimilar in Japan – as well as five drugs from Novartis.
Also, deals involving Immunomic, Replicate, Biocon, DKSH, Genor, G1, Daiichi Sankyo, Esperion, Alteogen, Gelesis, China Medical System Holdings, Sosei and EverInsight.
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Heptares Therapeutics Limited
- Heptares Zurich
- G7 Therapeutics
- Sosei Heptares